• AstraZeneca paused its coronavirus vaccine trials
• US equities try to rebound from a US-led tech rout
European indices ended higher, erasing previous sessions losses as the tech sell-off in the US slowed down. Still, sentiment was hit by the possibility that AstraZeneca Covid-19 vaccine could be delayed after a person participating in one of the studies got sick. Stat News reported that the patient had a serious neurological symptom but he's improving and could be discharge from hospital today. Tomorrow markets’ attention will focus on the ECB monetary policy decision as investors will be looking for further hints on when more stimulus will be added through the pandemic emergency purchase programme. During today's session DAX 30 rose 2.1%, CAC 40 gained 1.6% and FTSE 100 finished 1.62% higher.
Gold prices rebounded to touch a near one-week high of $1,949 an ounce while silver price is approaching $27 resistance level, amid a slightly weaker dollar. WTI crude prices rose more than 4% to trade around $38.3 a barrel, while Brent crude futures gained more than 3.4% to trade around $41.10 a barrel, partially erasing some of the previous session’s heavy losses. Oil traders now await the API report which will be released in the evening.

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.